Download PDF
Thromb Haemost 1961; 6(02): 235-247
DOI: 10.1055/s-0038-1654556
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Influence of Contact and Prothrombin on Intermediate Product I Formation

J. N Shanberge   *
1   Coagulation Laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier) Kantonsspital, University of Zürich, Switzerland
,
F Duckert
1   Coagulation Laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier) Kantonsspital, University of Zürich, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

    Permissions and Reprints

Summary

In the in vitro generation of intermediate product I, in which non-purified components are used, both prothrombin and foreign surface “contact” are essential for the formation of optimum activity. Most of the time interval required before optimum intermediate product I activity is reached is the time needed for potentiation of intermediate product I as well as for the conversion of prothrombin to thrombin. In the system studied, it is felt that, in the absence of prothrombin, intermediate product I activity is blocked by the presence of an inhibitor. The action of thrombin would then be to overcome the inhibitor. The apparent increase in factor IX activity, observed during the generation of intermediate product I as measured by the one-stage method, is due to the non-specific clot-promoting effect of intermediate product I on the assay.

* Investigation carried out during the tenure of a Special Fellowship from the American Heart Institute, United States Public Health Service.


 

  • References

  • (1) Bergsagel D. E, Hougie C. Intermediate Stages in the Formation of Blood Thromboplastin. Brit. J. Haemat. 2: 113 1956;
    CrossrefPubMedGoogle Scholar
  • (2) Duckert F, Koller F, Matter M. Purification and Physiological Properties of Factor VII from Plasma and Serum. Separation from Prothrombin. Proc. Soc. exp. Biol (N. Y.) 82: 259 1953;
    CrossrefPubMedGoogle Scholar
  • (3) Fisch U, Duckert F. Some Aspects of Kinetics of the First Stages of Blood Thromboplastin Formation. Thromb. Diath. haem. 3: 98 1959;
    PubMedGoogle Scholar
  • (4) Geiger M, Duckert F, Koller F. Quantitative Bestimmungen von Faktor VIII und IX bei Blutersippen. 413 5th Congress Europ. Soc. Haemat. Freiburg i. Br. 1955. Springer; Heidelberg: 1956
    Google Scholar
  • (5) Koller F, Loeliger A, Duckert F. Experiments on a New Clotting Factor. Factor VII. Acta haemat. (Basel) 6: 1 1951;
    CrossrefPubMedGoogle Scholar
  • (6) Mayer G, Mayer S, Waitz R. Consommation de la Globuline Antihémophilique et Pouvoir Thromboplastino-accélérateur du Premier Produit Intermédiaire (P.P.I.). Effet Koller et Consommation de la Globuline Antihémophilique (A.H.G.). Rev. franç. Ét. clin. biol. 6: 168 1961;
    PubMedGoogle Scholar
  • (7) Soulier J.-P, Prou-Wartelle O. Nouvelles Données sur les Facteurs Hageman et P.T.A. et sur le “Contact”. Rev. franc. Ét. clin. biol. 4: 932 1959;
    PubMedGoogle Scholar
  • (8) Spaet T. H, Cintron J. Studies on the Formation and Inactivation of Human Blood Coagulation Product I. Thromb. Diath. haem. 5: 447 1961;
    PubMedGoogle Scholar
  • (9) Streuli F. On the Purification and Conversion of Human Prothrombin. Thromb. Diath. haem. 3: 194 1959;
    PubMedGoogle Scholar
  • (10) Yin E. T, Duckert F. The Formation of Intermediate Product I in a Purified System. The Role of Factor IX or its Precursor and of Hageman Factor and PTA Fraction. Thromb. Diath. haem. 6: 224 1961;
    PubMedGoogle Scholar
  • (11) Yin E. T, Duckert F. Purification of Factor IX or Its Precursor and of a Hageman Factor and PTA Fraction. Thromb. Diath. haem. 6: 215 1961;
    PubMedGoogle Scholar